ATE237342T1 - Inhibitoren der leukozytenadhäsion - Google Patents

Inhibitoren der leukozytenadhäsion

Info

Publication number
ATE237342T1
ATE237342T1 AT95925545T AT95925545T ATE237342T1 AT E237342 T1 ATE237342 T1 AT E237342T1 AT 95925545 T AT95925545 T AT 95925545T AT 95925545 T AT95925545 T AT 95925545T AT E237342 T1 ATE237342 T1 AT E237342T1
Authority
AT
Austria
Prior art keywords
leukocyte adhesion
adhesion inhibitors
peptides
inhibitors
inflammatory
Prior art date
Application number
AT95925545T
Other languages
English (en)
Inventor
Eugene D Thorsett
Theodore A Yednock
Michael A Pleiss
Original Assignee
Athena Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/467,580 external-priority patent/US6001809A/en
Application filed by Athena Neurosciences Inc filed Critical Athena Neurosciences Inc
Application granted granted Critical
Publication of ATE237342T1 publication Critical patent/ATE237342T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT95925545T 1994-07-11 1995-07-10 Inhibitoren der leukozytenadhäsion ATE237342T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27305594A 1994-07-11 1994-07-11
US08/467,580 US6001809A (en) 1994-07-11 1995-06-06 Inhibitors of leukocyte adhesion
PCT/US1995/008516 WO1996001644A1 (en) 1994-07-11 1995-07-10 Inhibitors of leukocyte adhesion

Publications (1)

Publication Number Publication Date
ATE237342T1 true ATE237342T1 (de) 2003-05-15

Family

ID=26955906

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95925545T ATE237342T1 (de) 1994-07-11 1995-07-10 Inhibitoren der leukozytenadhäsion

Country Status (7)

Country Link
EP (1) EP0769958B1 (de)
JP (1) JPH10506608A (de)
AT (1) ATE237342T1 (de)
AU (1) AU2964295A (de)
CA (1) CA2193508A1 (de)
DE (1) DE69530392D1 (de)
WO (1) WO1996001644A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
NO970866L (no) * 1996-02-28 1997-08-29 Target Therapeutics Inc Infusjons-kateter med oppblåsbar membran
SE9603465D0 (sv) * 1996-09-23 1996-09-23 Astra Ab New compounds
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
WO1998054207A1 (en) * 1997-05-30 1998-12-03 Celltech Therapeutics Limited Anti-inflammatory tyrosine derivatives
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6069163A (en) * 1997-10-21 2000-05-30 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors
US6511961B1 (en) 1997-11-13 2003-01-28 Toray Industries, Inc. Cyclic peptides and medicinal use thereof
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
US6090841A (en) * 1997-11-21 2000-07-18 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
FR2773476B1 (fr) 1998-01-13 2001-02-23 Oreal Composition tinctoriale et procedes de teinture des fibres keratiniques la mettant en oeuvre
FR2773475B1 (fr) * 1998-01-13 2001-02-02 Oreal Composition tinctoriale et procedes de teinture des fibres keratiniques la mettant en oeuvre
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
BR0007663A (pt) 1999-01-22 2002-05-07 Elan Pharm Inc Derivados de acila para uso no tratamento de doenças relacionadas com o vla-4
AU3348800A (en) * 1999-01-22 2000-08-07 Elan Pharmaceuticals, Inc. Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
AR035476A1 (es) 1999-01-22 2004-06-02 Elan Pharm Inc Compuestos heteroarilo y heterociclicos con anillo fusionado, los cuales inhiben la adhesion de leucocitos mediada por vla-4, composiciones farmaceuticas, el uso de las mismas para la manufactura de un medicamento y un metodo para fijar vla-4 en una muestra biologica
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
CA2359114A1 (en) * 1999-01-25 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
EP1144435B1 (de) * 1999-01-26 2006-04-12 Elan Pharmaceuticals, Inc. Pyroglutaminsäurederivate und damit verwandte verbindungen, die die durch vla-4 vermittelte leukozytenadhäsion verringern
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
WO2000051974A1 (en) * 1999-03-01 2000-09-08 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 - receptor antagonists
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
WO2001009188A1 (en) * 1999-07-29 2001-02-08 Dyax Corp. Binding moieties for fibrin
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
NZ519447A (en) 1999-12-16 2004-03-26 Biogen Inc Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
IL149758A0 (en) 1999-12-28 2002-11-10 Pfizer Prod Inc Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
EP1332132B1 (de) 2000-04-17 2007-10-10 UCB Pharma, S.A. Enamin-derivate als zell-adhäsionsmoleküle
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
JP2004502762A (ja) 2000-07-07 2004-01-29 セルテック　アール　アンド　ディ　リミテッド 二環性ヘテロ芳香環を含有するインテグリンアンタゴニストとしてのスクエア酸誘導体
US6794506B2 (en) 2000-07-21 2004-09-21 Elan Pharmaceuticals, Inc. 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
US6803370B2 (en) 2000-07-21 2004-10-12 Elan Pharmaceuticals, Inc. Alpha amino acid derivatives—inhibitors of leukocyte adhesion mediated by VLA-4
PE20020384A1 (es) 2000-07-21 2002-05-28 Schering Corp PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C
TWI284539B (en) 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
EP1423135A4 (de) 2001-08-06 2006-06-07 Univ California Verfahren zur hemmung der angiogenese
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
EP2336184B1 (de) 2002-02-25 2014-12-03 Biogen Idec MA Inc. Verabreichung von Wirkstoffen zur Behandlung von Entzündungen
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
WO2004041279A1 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
WO2004066931A2 (en) 2003-01-24 2004-08-12 Elan Pharmaceuticals Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
WO2005070921A1 (en) 2004-01-23 2005-08-04 Elan Pharmaceuticals, Inc. Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
AU2005234596B8 (en) 2004-04-13 2011-06-16 Incyte Holdings Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
US7205310B2 (en) 2004-04-30 2007-04-17 Elan Pharmaceuticals, Inc. Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4
EP1901778A2 (de) 2005-07-08 2008-03-26 Elan Pharmaceuticals Inc. Herstellung von polymerkonjugaten von therapeutischen und landwirtschaftlichen verbindungen sowie lebensmittelzusatzverbindungen
ATE493405T1 (de) 2005-09-29 2011-01-15 Elan Pharm Inc Pyrimidinylamidverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
ZA200803016B (en) 2005-09-29 2009-10-28 Elan Pharmaceuticals Inc Wyeth Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
MEP1008A (xx) 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
WO2007101165A1 (en) 2006-02-27 2007-09-07 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
GB0724953D0 (en) * 2007-12-20 2008-01-30 Lytix Biopharma As Methods of peptide modification
WO2010031183A1 (en) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists
EA020470B1 (ru) 2008-11-26 2014-11-28 Пфайзер Инк. 3-аминоциклопентанкарбоксамиды в качестве модуляторов рецептора хемокина
US20100204221A1 (en) 2009-02-09 2010-08-12 Hariprasad Vankayalapati Pyrrolopyrimidinyl axl kinase inhibitors
US8394819B2 (en) 2009-02-24 2013-03-12 Merck Sharp & Dohme Corp. Indole derivatives as CRTH2 receptor antagonists
JP2012525336A (ja) 2009-04-27 2012-10-22 エラン ファーマシューティカルズ，インコーポレイテッド α−４インテグリンのピリジノンアンタゴニスト
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
AU2011349524B2 (en) 2010-12-23 2016-06-02 Merck Sharp & Dohme Corp. Quinoxalines and aza-quinoxalines as CRTH2 receptor modulators
MX2013012776A (es) 2011-05-04 2013-11-21 Merck Sharp & Dohme Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
EP2720545B1 (de) 2011-06-17 2016-11-30 Merck Sharp & Dohme Corp. Cycloalkyl-fusionierte tetrahydrochinoline als crth2-rezeptor-modulatoren
EP2763975B1 (de) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. 3-pyridyl-carboxamidhaltige milztyrosinkinase-(syk)-hemmer
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
CN113330013B (zh) 2019-01-10 2022-12-27 石药集团中奇制药技术（石家庄）有限公司 杂环化合物盐及其应用
EP4284947A1 (de) 2021-01-29 2023-12-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur beurteilung des risikos der entwicklung progressiver multifokaler leukoenzephalopathie bei patienten mit vla-4-antagonisten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705752D0 (en) * 1987-03-11 1987-04-15 Royal Postgrad Med School Diagnostic agents
EP0364690A3 (de) * 1988-08-23 1990-07-18 Dana Farber Cancer Institute Alpha-Subeinheit des Mac-1-Leukocyt-Adhäsions-Rezeptors
WO1994005314A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
JPH08503694A (ja) * 1992-09-08 1996-04-23 セントコー・インコーポレーテッド ペプチド系の細胞接着阻害物質
JPH09500100A (ja) * 1993-05-05 1997-01-07 アフィマックス テクノロジーズ エヌ ブィ Ｅｌａｍ−１に結合するペプチド類及び化合物類
AU693143B2 (en) * 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same

Also Published As

Publication number Publication date
EP0769958A1 (de) 1997-05-02
AU2964295A (en) 1996-02-09
EP0769958B1 (de) 2003-04-16
CA2193508A1 (en) 1996-01-25
WO1996001644A1 (en) 1996-01-25
JPH10506608A (ja) 1998-06-30
DE69530392D1 (de) 2003-05-22
EP0769958A4 (de) 1999-11-24

Similar Documents

Publication Publication Date Title
DE69530392D1 (de) Inhibitoren der leukozytenadhäsion
NO20030895L (no) Ny anvendelse av dipeptidyl peptidase IV inhibitorer
ES2149888T3 (es) 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias.
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
BG102241A (bg) Инхибитори на клетъчна адхезия
ATE515514T1 (de) Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
DE69935133D1 (de) Antagoniste zur behandlung von cd11/cd18 adhäsionsrezeptor-vermittelten krankheiten
MX9702797A (es) Agentes de enlace a cd23.
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
BG101841A (bg) Инхибитори на клетъчна адхезия
BR9408450A (pt) Antagonistas da neuroquinina diazabiciclicos
DE60024415D1 (de) Die glycin-betain für seine antithrombotische verwendung
ATE389023T1 (de) Kontrolle der schotendehiszenz
BR9808923B1 (pt) processos para fazer compostos inibidores de ciclooxigenase-2, e, compostos intermediÁrios para fazer inibidores de ciclooxigenase-2.
HUT76926A (hu) Új elasztáz inhibitorok
ES2142490T3 (es) Ciclopeptolidos.
DK1183025T3 (da) Hæmmere af proton-styrede kationskanaler og deres anvendelse til behandling af iskæmiske lidelser
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
DE69736180D1 (de) Behandlung von manischen erkrankungen
DE60023139D1 (de) Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
DE50309647D1 (de) Ng fibrotischer erkrankungen
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
MX9804048A (es) Ciclopeptolidos.
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties